公开(公告)号：US20240038393A1

公开(公告)日：2024-02-01

申请号：US18449632

申请日：2023-08-14

Applicant: GENENTECH, INC. ,  HOFFMANN-LA ROCHE INC.

Inventor： Xiao Li ,  Marius Rene Garmhausen ,  Gunther Jansen ,  Teresa Melanie Karrer

IPC: G16H50/20 ,  G16H50/30 ,  G16H30/40 ,  G16B25/10 ,  G16B40/20

CPC classification number: G16H50/20 ,  G16H50/30 ,  G16H30/40 ,  G16B25/10 ,  G16B40/20

Abstract: In some embodiments, a current state of a medical condition or a progression of the medical condition is predicted by processing one or more digital pathology images and expression levels of genes using a machine-learning model. In some embodiments, one or more predicted gene-expression levels are generated by processing a data set corresponding to one or more digital pathology images using a machine-learning model. In some embodiments, one or more predicted digital pathology metrics are generated by processing a data set that corresponds to expression levels of a set of genes using a machine-learning model.

公开(公告)号：US20240035032A1

公开(公告)日：2024-02-01

申请号：US18114626

申请日：2023-02-27

Applicant: Hoffmann-La Roche Inc.

Inventor： Hassan JAVANBAKH ,  Søren OTTOSEN ,  Morten LINDOW

IPC: C12N15/113 ,  A61K47/54 ,  A61K31/713

CPC classification number: C12N15/1131 ,  A61K47/549 ,  A61K47/554 ,  C12N15/1133 ,  A61K31/713 ,  C12N2310/351 ,  C12N2320/30 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/346 ,  C12N2310/3515

Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.

公开(公告)号：US20240019424A1

公开(公告)日：2024-01-18

申请号：US18451352

申请日：2023-08-17

Applicant: Hoffmann-La Roche Inc.

Inventor： Tony Christopeit ,  Tilman Schlothauer

IPC: G01N33/543 ,  G01N33/68

CPC classification number: G01N33/54373 ,  G01N33/6854 ,  G01N2333/70535

Abstract: Herein is reported a method for determining antibody-FcRn-interaction comprising the steps of immobilizing FcRn on a solid surface, which is suitable for surface plasmon resonance measurement, individually applying to the solid surface obtained in step a) solutions comprising the antibody at different concentrations and determining the association rate constant and the dissociation rate constant for each concentration, and determining with the rates obtained in step b) the KD-value of the antibody-FcRn-interaction, wherein the immobilized FcRn is monomeric FcRn, the monomeric FcRn is immobilized using functional (capture) groups that are directly attached to said solid surface, the solid surface is free of branched glucan, and the immobilization is at a pH value of from pH 7 to pH 8.

公开(公告)号：US20240011066A1

公开(公告)日：2024-01-11

申请号：US18303451

申请日：2023-04-19

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Shahram Misaghi ,  Amy Shen ,  Inn Huam Yuk ,  Gavin Christian Barnard ,  Simon Auslaender ,  Niels Bauer ,  Benedikt Oswald

IPC: C12P21/02 ,  C12N15/90 ,  C12N15/11 ,  C12N9/00 ,  C12N9/22 ,  C12N9/10 ,  C12N9/86

CPC classification number: C12P21/02 ,  C12N15/907 ,  C12N15/11 ,  C12N9/93 ,  C12N9/22 ,  C12N9/1029 ,  C12Y203/01 ,  C12N9/86 ,  C12Y305/02006 ,  C12N2310/20 ,  C12N2800/80

Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.

公开(公告)号：US20230416391A1

公开(公告)日：2023-12-28

申请号：US18326605

申请日：2023-05-31

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Huang HUANG ,  Carol Elaine O'HEAR ,  Iris Tranthuyngan TO ,  Michael Ching-sun WEI ,  Shen YIN

IPC: C07K16/28 ,  A61K9/00 ,  A61K31/138 ,  A61K31/167 ,  A61K31/573 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2887 ,  C07K16/2809 ,  A61K9/0019 ,  A61K31/138 ,  A61K31/167 ,  A61K31/573 ,  A61K39/3955 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/24 ,  A61K2039/55

Abstract: The present invention relates to the treatment of elderly subjects (e.g., subjects aged 65 years or older) having relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL). More specifically, the invention pertains to the treatment of subjects having an R/R NHL by intravenous administration of mosunetuzumab.

公开(公告)号：US11854168B2

公开(公告)日：2023-12-26

申请号：US18054337

申请日：2022-11-10

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Eldad Klaiman

IPC: G06T5/00 ,  G16H30/40 ,  G06N20/00 ,  G06N3/04

CPC classification number: G06T5/005 ,  G06N3/04 ,  G06N20/00 ,  G16H30/40 ,  G06T2207/20081 ,  G06T2207/20084

Abstract: The method includes generating, for each of a plurality of original images, a first artificially degraded image by applying a first image-artifact-generation logic on each of the original images; and generating the program logic by training an untrained version of a first machine-learning logic that encodes a first artifacts-removal logic on the original images and their respectively generated first degraded images; and returning the trained first machine-learning logic as the program logic or as a component thereof. The first image-artifact-generation logic is A) an image-acquisition-system-specific image-artifact-generation logic or B) a tissue-staining-artifact-generation logic.

公开(公告)号：US20230399396A1

公开(公告)日：2023-12-14

申请号：US17819064

申请日：2022-08-11

Applicant: Hoffmann-La Roche Inc.

Inventor： Josef Endl ,  Jens Fischer ,  Peter Kern ,  Sonja Offner ,  Josef Platzer ,  Stefan Seeber

IPC: C07K16/28 ,  C07K16/00 ,  C12N5/0781

CPC classification number: C07K16/28 ,  C07K16/00 ,  C12N5/0635 ,  C07K2317/14 ,  C12N2501/2302 ,  C12N2501/2321 ,  C12N2501/52 ,  C12N2502/99 ,  C12N2510/00

Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of TL-2 and TL-21.

公开(公告)号：US20230391823A1

公开(公告)日：2023-12-07

申请号：US18454131

申请日：2023-08-23

Applicant: Hoffmann-La Roche Inc.

Inventor： Roberto Falkenstein ,  Christoph Feistl ,  Thorsten Lemm ,  Marc Pompiati ,  Bernhard Spensberger

IPC: C07K1/34 ,  B01D37/02 ,  B01D39/16 ,  B01D39/18 ,  B01D39/20

CPC classification number: C07K1/34 ,  B01D37/025 ,  B01D39/163 ,  B01D2239/0407 ,  B01D39/2079 ,  B01D2201/085 ,  B01D39/18

Abstract: Herein is reported a method for the purification or production of a therapeutic polypeptide using the same depth filter multiple times, i.e. a depth filter which has been used before and has been regenerated.
Reported herein is a method for purifying or producing a therapeutic polypeptide, characterized in that the method comprises the following steps:



a) filtering an aqueous composition containing said therapeutic polypeptide and impurities through a depth filter, recovering the flow-through and thereby obtaining said purified therapeutic polypeptide,
b) contacting said depth filter with a regeneration solution and thereby regenerating the depth filter, and
c) repeating steps a) and b) one or more times.

公开(公告)号：US20230391764A1

公开(公告)日：2023-12-07

申请号：US18454315

申请日：2023-08-23

Applicant: Hoffmann-La Roche Inc.

Inventor： Hongying YUN ,  Bo ZHANG ,  Xiufang ZHENG

IPC: C07D417/12 ,  A61P31/14

CPC classification number: C07D417/12 ,  A61P31/14

Abstract: The present invention provides novel compounds having the general formula:




wherein R1, R2, L, and A are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.

公开(公告)号：US11827711B2

公开(公告)日：2023-11-28

申请号：US16929000

申请日：2020-07-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Stefan Dengl ,  Guy Georges ,  Ralf Hosse ,  Inja Waldhauer ,  Christian Klein ,  Pablo Umana

IPC: C07K16/28

CPC classification number: C07K16/2851 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/565

Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.